35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers

• DOI: 10.1016/j.annonc.2021.01.050
• Publication Date: 2021-03-02T21:27:34Z
• Authors: E. Dardenne; F. Padilla; S. Rasmussen; S.N. Yang; A. Mentes; L.S. Ogawa; R. Fiorenza; A. Trombino; S. Smith; D. Romashko; N. Ishiyama; M. Chevtsova; S. Thakur; E. Rosfjord; E. Buck; C. Roberts; M. Lucas; T-A. Lin
• Keywords: 03 medical and health sciences; 0302 clinical medicine